Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma.

Authors: Zhang, Ying  Li, Tao  Qiu, Yumin  Zhang, Tao  Guo, Pengbo  Ma, Xiaomin  Wei, Qing  Han, Lihui 
Citation: Zhang Y, etal., Medicine (Baltimore). 2017 Jan;96(2):e5642. doi: 10.1097/MD.0000000000005642.
Pubmed: (View Article at PubMed) PMID:28079796
DOI: Full-text: DOI:10.1097/MD.0000000000005642

Unique change of circulating microRNAs (miRNAs) was recognized to occur in early oncogenesis, which conferred it the potential as biomarkers for early detection of cancer. However, its diagnostic capability for hepatocellular carcinoma (HCC) has not been fully understood. In this study, microarray analysis was applied to screen the initial candidate miRNA from both the supernatants of anoikis-resistant cellular models and the sera samples of HCC patients. The selected differentially expressed miRNAs were further verified in 115 HCC patients and 40 health controls by qRT-PCR. Among these, 4 miRNAs (miR-16-2-3p, 92a-3p, 107, and 3126-5p) were significantly changed in HCC patients compared with controls. Logistic regression analysis identified a 3-miRNA panel (miR-92-3p, miR-107, and miR-3126-5p) as valuable diagnostic marker for HCC, especially for early stage patients (AUC = 0.975) and for low-level AFP HCC patients (AUC = 0.971). In addition, the combination of 3-miRNA panel and AFP was even more effective for discriminating the early stage HCC patients (AUC = 0.988) and low-level AFP HCC patients (AUC = 0.989) from control. In conclusion, diagnostic efficacy of the combination of 3-miRNA panel and AFP was powerful for HCC diagnosis, especially in early tumor screening and low-level AFP patients.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 14975300
Created: 2019-10-07
Species: All species
Last Modified: 2019-10-07
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.